Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.67 |
| ▸ | PCSK9 | Q8NBP7 | 6/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | CASR | P41180 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11039079 | 0.84 | AHR (0.60) | AHRPCSK9LOXL2CASR | |
| SCHEMBL29403791 | 0.81 | LOXL2 (0.69) | AHRPCSK9LOXL2 | |
| SCHEMBL401081 | 0.81 | LOXL2 (0.69) | AHRPCSK9LOXL2 | |
| SCHEMBL28338445 | 0.81 | LOXL2 (0.69) | AHRPCSK9LOXL2 | |
| SCHEMBL12852216 | 0.80 | AHR (1.00) | AHRPCSK9LOXL2 | |
| SCHEMBL29886525 | 0.80 | AHR (1.00) | AHRPCSK9LOXL2 | |
| SCHEMBL31672301 | 0.79 | AHR (0.62) | AHRPCSK9LOXL2 | |
| SCHEMBL7499115 | 0.79 | PCSK9 (0.63) | AHRPCSK9LOXL2 | |
| SCHEMBL7490425 | 0.79 | PCSK9 (0.63) | AHRPCSK9LOXL2 | |
| SCHEMBL7491887 | 0.79 | PCSK9 (0.63) | AHRPCSK9LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2021179088-A1 | TERPENE-ENHANCED COMPOSITIONS AND USES THEREOF | HEXO OPERATIONS INC. (CA) | 2021-09-16 | — | — | WO | claimed |
| WO-2021179087-A1 | TERPENE-ENHANCED COMPOSITIONS AND USES THEREOF | HEXO OPERATIONS INC. (CA) | 2021-09-16 | — | — | WO | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-20180021247-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | Kannalnnovations LLC (US) | 2018-01-25 | — | — | US | claimed |
| WO-2017027553-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | KannaInnovations LLC (US) | 2017-02-16 | — | — | WO | claimed |
| US-20170042791-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | KannaInnovations LLC (US) | 2017-02-16 | — | — | US | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2024113046-A1 | VAPORIZABLE CANNABINOID COMPOSITIONS | ZEST CANNABIS INC. (CA) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024108201-A2 | CANNABIGEROLIC ACID (CBGA) AND CANNABIGEROL (CBG) DERIVED PRODUCTS AND METHODS OF USE | Bazelet Health Systems, Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240139268-A1 | HYBRID HASHISH-BASED CONSUMER PRODUCTS | HEXO OPERATIONS INC. (CA) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073762-A2 | COMPOSITIONS FOR IMPROVING HEALTH | SHAMAN NATURALS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240082270-A1 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | BAZELET HEALTH SYSTEMS INC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2020037410-A1 | CANNABIS-INFUSED PRODUCT WITH ENHANCED CANNABINOID PROFILE USER EXPERIENCE | HEXO OPERATIONS INC. (CA) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020037406-A1 | CANNABINOID-CONTAINING CONSUMER PRODUCT SYSTEMS, APPARATUS AND METHODS | HEXO OPERATIONS INC. (CA) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020037411-A1 | CANNABINOID BASED EMULSION SYSTEMS FOR INFUSED AQUEOUS COMPOSITIONS | HEXO OPERATIONS INC. (CA) | 2020-02-27 | — | — | WO | disclosed |
| US-20180021247-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | Kannalnnovations LLC (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2017027553-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | KannaInnovations LLC (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170042791-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | KannaInnovations LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-20160025753-A1 | ASSAY FOR CANNABINOIDS AND METHODS OF USE THEREOF | MICROGENICS CORPORATION | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | AHR 359/4885PCSK9 3503/4885LOXL2 1697/4885 |
| US-20170042791-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | CNR2, CNR1, HCAR3 | AHR 47/4885PCSK9 1587/4885LOXL2 587/4885 |
| US-20180021247-A1 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | CNR2, CNR1, HCAR3 | AHR 47/4885PCSK9 1587/4885LOXL2 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.